The final determination also adds coverage for FDA-approved tests in stage III patients, and for repeat testing if patients receive a new primary diagnosis.

The decision, which the company said was made for business and financial reasons, raises questions about the viability of such tests in the face of reimbursement uncertainly.

The company plans to use the new funding to expand into Asia, with a particular focus on China.

The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.

Thermo Fisher said that IntegenX complements and enhances its existing human identification product portfolio.

An impetus for the review included the fact that companies are advertising and promoting liquid biopsy in areas where the technology has not yet proven its clinical utility.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by

Machine learning is a field of computer science that gives computers the ability to learn without being explicitly programmed. This webinar explores the basics of machine learning, focusing on the industry standard CRISP-DM (Cross Industry Standard Process for Data Mining), and how to apply the method to a molecular diagnostic technique such as PCR. The webinar also discusses the implications of current PCR analysis software and the lack of artificial intelligence. Lastly - a novel and improved way of analyzing PCR results is introduced.

This application note demonstrates that:

• The new Applied Biosystems SeqStudio Genetic Analyzer generates high-quality data from multiplex ligation–dependent probe amplification (MLPA) assays developed by MRC-Holland.

• The SeqStudio Genetic Analyzer provides fast and efficient results; each run cycle accommodates 4 MLPA reaction samples and can be completed within 45 min.